Cemiplimab

Cemiplimab (trade name Libtayo) is a monoclonal antibody drug for the treatment of squamous cell skin cancer,[1] myeloma,[2] and lung cancer.[3]

Cemiplimab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	PD-1
Clinical data
Trade names	Libtayo
Other names	REGN-2810
AHFS/Drugs.com	libtayo
ATC code	L01XC33 (WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Elimination half-life	19 days
Identifiers
CAS Number	1801342-60-8
DrugBank	DB14707
ChemSpider	none
UNII	6QVL057INT
KEGG	D11108
Chemical and physical data
Formula	C₆₃₈₀H₉₈₀₈N₁₆₈₈O₂₀₀₀S₄₄
Molar mass	143569.10 g·mol⁻¹

In Sept 2018 it was approved by the US FDA for treating "patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation".[4]

Mechanism of action

It targets PD-1 so it acts as a checkpoint inhibitor.[5]

References

H. Spreitzer (2 January 2018). "Neue Wirkstoffe: Cemiplimab". Österreichische Apothekerzeitung (in German) (1/2018).
Clinical trial number NCT03194867 for "Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients" at ClinicalTrials.gov
Clinical trial number NCT03430063 for "A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer" at ClinicalTrials.gov
FDA approves first treatment for advanced form of the second most common skin cancer 28 Sept 2018
New PD-1 Inhibitor OK'd for Cutaneous SCC - Sixth PD-1/PD-L1 checkpoint inhibitor approved by agency 2018

Monoclonal antibodies for the immune system

Immune system ("-l(i[m])-")

Human ("-limu-")	Immunosuppression: Abrilumab Adalimumab Anifrolumab^† Atorolimumab Avelumab Belimumab Bleselumab Brodalumab Camidanlumab tesirine Carlumab Cemiplimab Dupilumab Eldelumab Emapalumab^† Fresolimumab Golimumab Ianalumab^† Lanadelumab Lenzilumab Lerdelimumab Lirilumab Mavrilimumab Metelimumab Morolimumab Namilumab Oleclumab Oxelumab§ Pamrevlumab Placulumab Relatlimab^† Sarilumab Sifalimumab Tabalumab Tezepelumab^† Ulocuplumab Varlilumab Immune activation: Ipilimumab Atezolizumab Durvalumab Nivolumab Pembrolizumab Tremelimumab^† Urelumab Other: Bertilimumab Zanolimumab
Mouse ("-limo-")	Afelimomab Elsilimomab Faralimomab Gavilimomab Inolimomab Maslimomab Nerelimomab Odulimomab Telimomab aritox Vepalimomab Zolimomab aritox
Chimeric ("-lixi-")	Andecaliximab^† Basiliximab Clenoliximab Galiximab Gomiliximab Infliximab Keliximab Lumiliximab Priliximab Teneliximab Vapaliximab
Humanized ("-lizu-")	Immunosuppressive: Aselizumab Apolizumab^§ Benralizumab Camrelizumab^† Cedelizumab Certolizumab pegol Crizanlizumab^† Daclizumab Eculizumab Efalizumab Epratuzumab Erlizumab Etrolizumab^† Fontolizumab Inebilizumab^† Itolizumab Lampalizumab^† Letolizumab Ligelizumab^† Lulizumab pegol Mepolizumab Mogamulizumab Natalizumab Ocrelizumab Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pembrolizumab Pexelizumab Pidilizumab Plozalizumab PRO 140^† Quilizumab Ravulizumab Reslizumab Rontalizumab Rovelizumab Ruplizumab Samalizumab Satralizumab^† Siplizumab Spartalizumab^† Talizumab Teplizumab Tislelizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab Vedolizumab Visilizumab Vobarilizumab TGN1412^§ Non-immunosuppressive: Ibalizumab
Chimeric + humanized ("-lixizu-")	Otelixizumab Sutimlimab^†

Interleukin ("-k(i[n])-")

Human ("-kinu-")	Bermekimab Brazikumab Briakinumab Canakinumab Fezakinumab Fletikumab Guselkumab Secukinumab Sirukumab Tralokinumab^† Ustekinumab
Humanized ("-kizu-", "-kinzu-")	Anrukinzumab Bimekizumab^† Clazakizumab Gevokizumab Ixekizumab Mirikizumab^† Lebrikizumab Olokizumab^† Perakizumab Risankizumab Tildrakizumab
Veterinary ("-kivet-")	Lokivetmab

Inflammatory lesions ("-les-")

Mouse ("-leso-")	Besilesomab Fanolesomab^‡ Lemalesomab Sulesomab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.